Posted by Michael Wonder on 03 Aug 2020
PolyPid granted fast track designation from FDA for D-PLEX for prevention of surgical site infections in abdominal surgery
3 August 2020 - PolyPid today announced that D-PLEX100 has received fast track designation from the U.S. FDA for the prevention of post abdominal surgery incisional infections.
PolyPid’s lead product candidate, D-PLEX100, is a novel product candidate designed to provide local prolonged anti-bacterial activity directly at the surgical site to prevent surgical site infection.
